Vertex Labs Review & Prices

Retatrutide is an experimental once-weekly injection from Eli Lilly (internal code LY3437943). It's a single molecule that activates three receptors: GIP, GLP-1, and glucagon. Tirzepatide covers the first two, and retatrutide adds the third. It isn't approved anywhere, for anything. Lilly has said it plans to file with the FDA in the first quarter of 2027. On Peptide Grading , we list the research-labeled vials with sizes, price per mg, and COAs side by side. Being listed there isn't an endorsement, and those vials aren't Lilly's product.

Tirzepatide is a first-in-class dual GIP and GLP-1 receptor agonist developed by Eli Lilly, FDA-approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound) including severe obstructive sleep apnea in adults with obesity. It is a 39-amino-acid peptide with a C20 fatty di-acid moiety that promotes albumin binding, enabling once-weekly dosing. Clinical trials consistently demonstrate it delivers the most substantial weight reduction among incretin-based therapies, with up to 22.5% mean body weight loss at 72 weeks.

Semaglutide started as something your own gut already makes. GLP-1 nudges the pancreas to release insulin and tells your brain you've eaten enough, and then it's gone in a couple of minutes. Not much use as a drug. So Novo Nordisk kept editing the molecule until it lasted about a week. That version ended up in Ozempic, Rybelsus, and Wegovy. The first two are for type 2 diabetes; Wegovy is the weight one, and you can't get any of them without a prescription. Most compounds on a research-peptide site have no approved use at all. Semaglutide does, and that changes how everything below should be read. Peptide Grading lists research-labeled semaglutide listings so vendors, vial sizes, price per mg, and COA documents sit side by side. A listing here is not the same thing as the prescription product.

BPC-157 is a 15-amino-acid peptide first described from gastric juice. Most of the published work is preclinical, with studies covering tendon, muscle, gastrointestinal, vascular, and other injury models. Researchers have looked at several signaling pathways, including VEGFR2, nitric oxide, Akt-eNOS, and ERK1/2 . Other work has focused on angiogenesis, fibroblast activity, endothelial responses, and inflammation. Human data are still sparse. Small studies have looked at knee pain, interstitial cystitis, and intravenous safety and pharmacokinetics , but the number of human studies remains small and larger controlled trials are not available.

CJC-1295 is a member of the GHRH analogue family of peptides and consists of a sequence derived from hGRF(1-29). The addition of a DAC group allows for prolonged exposure by binding to albumin compared to native GHRH. That longer exposure is what makes CJC-1295 interesting in human pharmacology. Studies have followed changes in GH and IGF-1 , along with the pharmacokinetic behavior of the DAC form. At Peptide Grading , CJC-1295 listings can be compared by material form, supplier, reported specifications, COA documentation, quantity, shipping and price per mg.

If you've ever seen a blue-tinted skincare serum, you've already met GHK-Cu. It's a copper-carrying tripeptide that was first pulled out of human blood plasma back in 1973, and it's been sitting in cosmetics for decades. What's newer is its life as a research peptide: vials of it, and blends like Glow and Klow that put it alongside BPC-157 and TB-500 . I'll say upfront that GHK-Cu is a bit unusual in this catalog. It has a long research history, and the skin-care version is a mainstream cosmetic ingredient. But no GHK-Cu drug is approved by the FDA, and the injectable side is much less studied than the creams. On Peptide Grading , we line up the research-labeled listings, with vendors, sizes, price per mg, and COAs , so you can see the differences. A listing isn't a recommendation to use it.

Ask five vendors what's in GLOW and you'll mostly get the same answer: GHK-Cu , BPC-157 and TB-500 in one vial. That's the whole formula. The name is a marketing label, not a pharmacological category, and the pitch is simple: a skin peptide plus two repair peptides, sold as a two-in-one. We pull GLOW listings from different vendors into one place, with vial size, price, shipping and COA links.

Ipamorelin is a five-amino-acid peptide that switches on the ghrelin receptor and makes the pituitary release growth hormone. Novo Nordisk researchers built it in the 1990s, and what made it interesting was how narrow its effect looked. Older compounds in the same family pushed up other hormones too. Ipamorelin mostly didn't. It has no approved use anywhere. A Phase 2 trial in the early 2000s tried it for a bowel problem after surgery, and it didn't work well enough to continue. So what's left is mostly lab and animal data, and the research-labeled vials that vendors sell. On Peptide Grading , we list those vials with vendors, sizes, price per mg, and COA documents in one place, so you can compare them without hunting through tabs.

Klow Stack is Glow plus KPV: four peptides ( GHK-Cu , BPC-157 , TB-500 , KPV) in one vial. Each one is researched for a different job, from tissue remodeling to inflammation. The catch is that the research is on the peptides individually, mostly in animals. Nobody has published results on the blend itself. Klow packs them into a single product instead of four separate vials. On Peptide Grading , we track Klow Stack listings in one place: vendors, vial sizes, price per mg, shipping details, and certificate of analysis (COA) documents, so you don't need ten tabs open to compare them.

MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded by a short open reading frame in the mitochondrial 12S rRNA region. Peptide Grading tracks MOTS-c vendors, quantities, prices, shipping details, and COA information to make research-product listings easier to compare.